Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Retained Earnings: 2020-2024

Historic Retained Earnings for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$1.1 billion.

  • Arcutis Biotherapeutics' Retained Earnings fell 3.99% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 3.99%. This contributed to the annual value of -$1.1 billion for FY2024, which is 14.26% down from last year.
  • Arcutis Biotherapeutics' Retained Earnings amounted to -$1.1 billion in FY2024, which was down 14.26% from -$981.9 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Retained Earnings registered a high of -$202.0 million during FY2020, and its lowest value of -$1.1 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$981.9 million (2023), whereas its average is -$941.2 million.
  • Data for Arcutis Biotherapeutics' Retained Earnings shows a maximum YoY tumbled of 102.13% (in 2021) over the last 5 years.
  • Arcutis Biotherapeutics' Retained Earnings (Yearly) stood at -$202.0 million in 2020, then crashed by 102.13% to -$408.3 million in 2021, then crashed by 76.29% to -$719.8 million in 2022, then tumbled by 36.41% to -$981.9 million in 2023, then decreased by 14.26% to -$1.1 billion in 2024.